|

Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE

RECRUITINGPhase 4Sponsored by Weill Medical College of Cornell University
Actively Recruiting
PhasePhase 4
SponsorWeill Medical College of Cornell University
Started2024-09-11
Est. completion2027-01
Eligibility
Age18 Years – 99 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06377371

Summary

The study team hypothesizes that it is feasible to intraoperatively detect tumor following \[CU64\]DOTATATE injection using the gamma probe device.

Eligibility

Age: 18 Years – 99 YearsHealthy volunteers accepted
Inclusion Criteria:

* High suspicion of meningioma necessitating surgical resection based on conventional MRI criteria, or diagnosis of meningioma based on pathology reports from prior resection with radiographic findings of suspected recurrent or residual tumor necessitating repeat surgery.

Exclusion Criteria:

* Pregnant or breastfeeding
* Patients undergoing endoscopic endonasal resection, eyebrow incision surgery, or any surgical procedure in which the neoprobe cannot be employed
* Patients with hypersensitivity to somatostatin analogs
* Patients with contraindications to conventional MRI
* Patients with prior history of cranial radiation therapy
* Patients currently enrolled in other therapeutic clinical trials related to meningioma will be excluded

Conditions2

CancerMeningioma

Locations1 site

New York-Presbyterian/Weill Cornell Medical Center
New York, New York, 10021
Jana Ivanidze, MD/PhD212-746-4587jai9018@med.cornell.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.